Holen Sie sich die Stockscreener-App
1.02
11.30%
-0.13
Handel nachbörslich:
1.02
Schlusskurs vom Vortag:
$1.15
Offen:
$1.08
24-Stunden-Volumen:
630
Relative Volume:
11.19
Marktkapitalisierung:
$N/A
Einnahmen:
$3.13M
Nettoeinkommen (Verlust:
$-40.29M
KGV:
-0.3188
EPS:
-3.2
Netto-Cashflow:
$-33.08M
1W Leistung:
-11.30%
1M Leistung:
-60.53%
6M Leistung:
+427.32%
1J Leistung:
+221.67%
1-Tages-Spanne:
$1.02
$1.08
1-Wochen-Bereich:
$1.02
$1.08
52-Wochen-Spanne:
$1.02
$1.15
Trevena Inc Stock (TRVN) Company Profile
Vergleichen Sie TRVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
1.02 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-15 | Eingeleitet | Oppenheimer | Perform |
| 2020-09-14 | Eingeleitet | Guggenheim | Buy |
| 2020-08-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-11-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-10-12 | Herabstufung | Needham | Buy → Hold |
| 2018-10-10 | Herabstufung | Jefferies | Buy → Hold |
| 2017-11-08 | Bestätigt | Needham | Buy |
| 2017-10-16 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2017-10-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-08 | Bestätigt | Needham | Buy |
| 2017-02-23 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Bestätigt | FBR & Co. | Outperform |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2016-05-17 | Bestätigt | FBR Capital | Outperform |
| 2016-05-17 | Bestätigt | Needham | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-01 | Bestätigt | Wedbush | Outperform |
| 2015-08-03 | Eingeleitet | Brean Capital | Buy |
Alle ansehen
Trevena Inc Aktie (TRVN) Neueste Nachrichten
TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm - ACCESS Newswire
Acute Pain Drug Pipeline Analysis: Market Overview, Trends, and Future Growth (2034) - openPR.com
Trevena to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Opioid Drugs Market in 2025-2032 Detailed Study Analysis with - openPR.com
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm - ACCESS Newswire
COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com
Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com
Highest-Paid CEOs2024 - AFL-CIO
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada
Trevena discontinues OLINVYK injection sales - Investing.com
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World
Finanzdaten der Trevena Inc-Aktie (TRVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
Kapitalisierung:
|
Volumen (24h):